Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.69 |
| ▸ | FLT1 | P17948 | 1/20 | 0.69 |
| ▸ | KDR | P35968 | 1/20 | 0.69 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.69 |
| ▸ | CDK8 | P49336 | 1/20 | 0.69 |
| ▸ | GSK3A | P49840 | 1/20 | 0.69 |
| ▸ | GSK3B | P49841 | 1/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4051575 | 0.90 | CSF1R (0.56) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL4053658 | 0.89 | TP53 (0.55) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL4708019 | 0.88 | CSF1R (0.53) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL3021825 | 0.88 | KDR (0.53) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL3029722 | 0.88 | CSF1R (0.53) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL4705975 | 0.87 | CSF1R (0.66) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL4708836 | 0.87 | CSF1R (0.70) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL3036044 | 0.86 | KDR (0.52) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL3040791 | 0.86 | TBXAS1 (0.59) | CSF1RFGFR1FLT1KDRCSNK1A1 | |
| SCHEMBL4051848 | 0.86 | TP53 (0.52) | CSF1RFGFR1FLT1KDRCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2010-08-12 | — | — | US | disclosed |
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | LABORATORIOS ALMIRALL, S. A. | 2009-04-30 | — | — | US | disclosed |
| US-7511038-B2 | Pyridazin-3(2H)-one derivatives and their use as PDE4 inhibitors | LABORATORIOS ALMIRALL S.A. (ES) | 2009-03-31 | — | — | US | disclosed |
| US-7491722-B2 | Pyridazin-3(2H)-one derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-02-17 | — | — | US | disclosed |
| US-7459453-B2 | Pyridazin-3(2H)-one derivatives as PDE4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-12-02 | — | — | US | disclosed |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | DAL PIAZ VITTORIO | 2008-10-30 | — | — | US | disclosed |
| EP-1575926-B1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL LAB (ES) | 2008-03-05 | — | — | EP | disclosed |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-23 | — | — | US | disclosed |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-08-03 | — | — | US | disclosed |
| EP-1682519-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2006-07-26 | — | — | EP | disclosed |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-03-09 | — | — | US | disclosed |
| EP-1575926-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005049581-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-06-02 | — | — | WO | disclosed |
| WO-2004058729-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | ALMIRALL PRODESFARMA SA (ES) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111819-A1 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | CSF1R 2535/4885FGFR1 1861/4885FLT1 693/4885 |
| US-20060173008-A1 | New pyridazin-3(2h)-one derivatives | PDE3A, PDE4A, PDE3B | CSF1R 2868/4885FGFR1 2317/4885FLT1 813/4885 |
| US-20070197536-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE7A | CSF1R 2518/4885FGFR1 3345/4885FLT1 2189/4885 |
| US-20080269235-A1 | PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE3A, PDE4B | CSF1R 4118/4885FGFR1 2580/4885FLT1 2382/4885 |
| US-20060052379-A1 | Pyridazin-3(2h)-one derivatives as pde4 inhibitors | PDE4A, PDE3A, PDE4B | CSF1R 4118/4885FGFR1 2580/4885FLT1 2382/4885 |
| US-20100204241-A9 | NEW PYRIDAZIN-3(2H)-ONE DERIVATIVES | PDE4A, PDE3A, PDE3B | CSF1R 2535/4885FGFR1 1861/4885FLT1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.